Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology, Autoimmune, and Vascular Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for PTPRJ drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTPRJ ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View PTPRJ Products |
| Gene Delivery | PTPRJ Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View PTPRJ Products |
| Benchmark Ab | Anti-PTPRJ (Sequence of Clinical/Research Leads) Recombinant positive control. |
View PTPRJ Products |
| Validator | PTPRJ siRNA Set For knockdown verification. |
View PTPRJ Products |
| Related Target A | EGFR PTPRJ acts as a key negative regulator of EGFR signaling; co-evaluation is critical for oncological efficacy. |
View EGFR Products |
| Related Target B | VEGFR2 PTPRJ dephosphorylates VEGFR2 to modulate angiogenesis; essential for vascular disease and solid tumor assays. |
View VEGFR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse eval | Human/Mouse/Cyno ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (other RPTPs) strictly verified by mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live PTPRJ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PTPRJ therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-specific antibodies and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting receptor-type tyrosine-protein phosphatase modulation to overcome tyrosine kinase inhibitor (TKI) resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Agonistic) | Academic & Biopharma Consortia | Colorectal Cancer, Glioma | Conformational stability assays (Need HEK293-expressed ECD-Fc) |
| Bispecific Antibody (PTPRJ x Tumor Antigen) | Innovative Biotech Startups | Solid Tumors (NSCLC, Breast) | Heterodimer validation and dual-binding kinetics (Need cross-reactive proteins) |
| Small Molecule / Peptide Inhibitors | Global Pharma Partnerships | Thrombosis, Vascular Disorders | Phosphatase activity assays (Need high-purity intracellular domain proteins) |